The CpG island methylator phenotype in colorectal cancer: Progress and problems

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 1, 2012, Pages 77-85

  Hughes, Laura A E ^a   Khalid de Bakker, Carolina A J ^a   Smits, Kim M ^a   van den Brandt, Piet A ^a   Jonkers, Daisy ^a   Ahuja, Nita ^b   Herman, James G ^b   Weijenberg, Matty P ^a   van Engeland, Manon ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CIMP; Colorectal adenoma; Colorectal carcinoma; CpG island; Epigenetics; Promoter methylation

Indexed keywords

CANCER CLASSIFICATION; CANCER RISK; CASE STUDY; COLORECTAL ADENOMA; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; ENVIRONMENTAL FACTOR; HUMAN; LABORATORY TEST; MOLECULAR PATHOLOGY; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; GUIDELINES AS TOPIC; HUMANS; PHENOTYPE;

EID: 81255179895     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.10.005     Document Type: Review

References (110)

1. Laird P.W. Cancer epigenetics. Hum. Mol. Genet. 2005, 1:R65-R76.
2. Kaneda A., Feinberg A.P. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res. 2005, 65:11236-11240.
3. Kaneda A., Yagi K. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci. 2011, 102:18-24.
4. Sakatani T., Kaneda A., Iacobuzio-Donahue C.A., et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005, 307:1976-1978.
5. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 2006, 6:107-116.
6. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
7. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
8. van Engeland M., Derks S., Smits K.M., et al. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 2011, 29:1382-1391.
9. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
10. Issa J.P. CpG island methylator phenotype in cancer. Nat. Rev. Cancer 2004, 4:988-993.
11. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
12. Wong J.J., Hawkins N.J., Ward R.L. Colorectal cancer: a model for epigenetic tumorigenesis. Gut 2007, 56:140-148.
13. Ogino S., Cantor M., Kawasaki T., et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006, 55:1000-1006.
14. An C., Choi I.S., Yao J.C., et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin. Cancer Res. 2005, 11:656-663.
15. Etoh T., Kanai Y., Ushijima S., et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol. 2004, 164:689-699.
16. Kim H., Kim Y.H., Kim S.E., et al. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J. Pathol. 2003, 200:23-31.
17. Kusano M., Toyota M., Suzuki H., et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006, 106:1467-1479.
18. Oue N., Oshimo Y., Nakayama H., et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci. 2003, 94:901-905.
19. Toyota M., Ahuja N., Suzuki H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999, 59:5438-5442.
20. Marsit C.J., Houseman E.A., Christensen B.C., et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res. 2006, 66:10621-10629.
21. Suzuki M., Shigematsu H., Iizasa T., et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006, 106:2200-2207.
22. Shen L., Ahuja N., Shen Y., et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J. Natl. Cancer Inst. 2002, 94:755-761.
23. Strathdee G., Appleton K., Illand M., et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001, 158:1121-1127.
24. Li Q., Jedlicka A., Ahuja N., et al. Concordant methylation of the ER and N33 genes in glioblastoma multiforme. Oncogene 1998, 16:3197-3202.
25. Sasaki M., Dharia A., Oh B.R., et al. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 2001, 61:97-102.
26. Sasaki M., Kaneuchi M., Sakuragi N., et al. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res. 2003, 63:3101-3106.
27. Fang F., Turcan S., Rimner A., et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 2011, 3:75ra25.
28. Garcia-Manero G., Daniel J., Smith T.L., et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 2002, 8:2217-2224.
29. Toyota M., Kopecky K.J., Toyota M.O., et al. Methylation profiling in acute myeloid leukemia. Blood 2001, 97:2823-2829.
30. Toyota M., Ahuja N., Ohe-Toyota M., et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8681-8686.
31. Noffsinger A.E. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu. Rev. Pathol. 2009, 4:343-364.
32. East J.E., Saunders B.P., Jass J.R. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol. Clin. North Am. 2008, 37:25-46.
33. Snover D.C. Serrated polyps of the large intestine. Semin. Diagn. Pathol. 2005, 22:301-308.
34. Snover D.C. Update on the serrated pathway to colorectal carcinoma. Hum. Pathol. 2011, 42:1-10.
35. Snover D.C., Jass J.R., Fenoglio-Preiser C., et al. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am. J. Clin. Pathol. 2005, 124:380-391.
36. Imai K., Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008, 29:673-680.
37. Herman J.G., Umar A., Polyak K., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6870-6875.
38. Dahlin A.M., Palmqvist R., Henriksson M.L., et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 2010, 16:1845-1855.
39. Ogino S., Nosho K., Kirkner G.J., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
40. Iacopetta B., Kawakami K., Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?. Int. J. Clin. Oncol. 2008, 13:498-503.
41. Jover R., Nguyen T.P., Perez-Carbonell L., et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011, 140:1174-1181.
42. Van Rijnsoever M., Elsaleh H., Joseph D., et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003, 9:2898-2903.
43. Barault L., Charon-Barra C., Jooste V., et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008, 68:8541-8846.
44. Samowitz W.S., Albertsen H., Herrick J., et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005, 129:837-845.
45. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
46. Ogino S., Kawasaki T., Kirkner G.J., et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn. 2007, 9:305-314.
47. Samowitz W.S. The CpG island methylator phenotype in colorectal cancer. J. Mol. Diagn. 2007, 9:281-283.
48. Curtin K., Slattery M.L., Samowitz W.S. CpG island methylation in colorectal cancer: past, present and future. Pathol. Res. Int. 2011, 902674.
49. Anacleto C., Leopoldino A.M., Rossi B., et al. Colorectal cancer "methylator phenotype": fact or artifact?. Neoplasia 2005, 7:331-335.
50. Eads C.A., Danenberg K.D., Kawakami K., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000, 28:E32.
51. Toyota M., Ohe-Toyota M., Ahuja N., et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:710-715.
52. van Rijnsoever M., Grieu F., Elsaleh H., et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002, 51:797-802.
53. Yamashita K., Dai T., Dai Y., et al. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 2003, 4:121-131.
54. Samowitz W.S., Albertsen H., Sweeney C., et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J. Natl. Cancer Inst. 2006, 98:1731-1738.
55. Slattery M.L., Curtin K., Wolff R.K., et al. Diet, physical activity, and body size associations with rectal tumor mutations and epigenetic changes. Cancer Causes Control 2010, 21:1237-1245.
56. Nosho K., Irahara N., Shima K., et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008, 3:e3698.
57. Ogino S., Kawasaki T., Kirkner G.J., et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 2006, 8:582-588.
58. Shen L., Toyota M., Kondo Y., et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18654-18659.
59. Hinoue T., Weisenberger D.J., Lange C.P., et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2011, 10.1101/gr.117523.11.
60. Goel A., Nagasaka T., Arnold C.N., et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007, 132:127-138.
61. Ahn J.B., Chung W.B., Maeda O., et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 2011, 117:1847-1854.
62. An B., Kondo Y., Okamoto Y., et al. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. Int. J. Cancer 2010, 127:2095-2105.
63. Chan A.O., Soliman A.S., Zhang Q., et al. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clin. Cancer Res. 2005, 11:8281-8287.
64. Frazier M.L., Xi L., Zong J., et al. Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Res. 2003, 63:4805-4808.
65. Lee S., Cho N.Y., Choi M., et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol. Int. 2008, 58:104-113.
66. Suehiro Y., Wong C.W., Chirieac L.R., et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin. Cancer Res. 2008, 14:2560-2569.
67. O'Brien M.J., Yang S., Mack C., et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 2006, 30:1491-1501.
68. Lee S., Cho N.Y., Yoo E.J., et al. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch. Pathol. Lab. Med. 2008, 132:1657-1665.
69. Karpinski P., Myszka A., Ramsey D., et al. Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. Cancer Epidemiol. 2010, 34:338-344.
70. Ang P.W., Loh M., Liem N., et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer 2010, 10:227-235.
71. Greco S.A., Chia J., Inglis K.J., et al. Thrombospondin-4 is a putative tumour-suppressor gene in colorectal cancer that exhibits age-related methylation. BMC Cancer 2010, 10:494-504.
72. Iacopetta B., Grieu F., Phillips M., et al. Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci. 2007, 98:1454-1460.
73. Kawakami K., Ooyama A., Ruszkiewicz A., et al. Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype. Br. J. Cancer 2008, 98:1555-1561.
74. Sanchez J.A., Krumroy L., Plummer S., et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br. J. Surg. 2009, 96:1196-1204.
75. Cheng Y.W., Pincas H., Bacolod M.D., et al. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin. Cancer Res. 2008, 14:6005-6013.
76. Kim J.H., Shin S.H., Kwon H.J., et al. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 2009, 455:485-494.
77. Arain M.A., Sawhney M., Sheikh S., et al. CIMP status of interval colon cancers: another piece to the puzzle. Am. J. Gastroenterol. 2010, 105:1189-1195.
78. Cai G., Xu Y., Lu H., et al. Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. Int. J. Colorectal Dis. 2008, 23:365-373.
79. Deng G., Kakar S., Tanaka H., et al. Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur. J. Cancer 2008, 44:1290-1301.
80. Kakar S., Deng G., Sahai V., et al. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. Arch. Pathol. Lab. Med. 2008, 132:958-964.
81. Kambara T., Simms L.A., Whitehall V.L., et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144.
82. Kim J.C., Choi J.S., Roh S.A., et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann. Surg. Oncol. 2010, 17:1767-1776.
83. Sugai T., Habano W., Jiao Y.F., et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J. Mol. Diagn. 2006, 8:193-201.
84. Jover R., Nguyen T.P., Perez-Carbonell L., et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011, 140:1174-1181.
85. de Vogel S., Wouters K.A., Godschalk R.W. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3086-3096.
86. English D.R., Young J.P., Simpson J.A., et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol. Biomarkers Prev. 2008, 17:1774-1780.
87. Limsui D., Vierkant R.A., Tillmans L.S., et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J. Natl. Cancer Inst. 2010, 102:1012-1022.
88. Chan A.O., Issa J.P., Morris J.S., et al. Concordant CpG island methylation in hyperplastic polyposis. Am. J. Pathol. 2002, 160:529-536.
89. O'Brien M.J., Yang S., Clebanoff J.L., et al. Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am. J. Surg. Pathol. 2004, 28:423-434.
90. Yang S., Farraye F.A., Mack C., et al. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 2004, 28:1452-1459.
91. Hiraoka S., Kato J., Tatsukawa M., et al. Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology 2006, 131:379-389.
92. Park S.J., Rashid A., Lee J.H., et al. Frequent CpG island methylation in serrated adenomas of the colorectum. Am. J. Pathol. 2003, 162:815-822.
93. Vaughn C.P., Wilson A.R., Samowitz W.S. Quantitative evaluation of CpG island methylation in hyperplastic polyps. Mod. Pathol. 2010, 23:151-156.
94. Velho S., Moutinho C., Cirnes L., et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255-261.
95. Rashid A., Shen L., Morris J.S., et al. CpG island methylation in colorectal adenomas. Am. J. Pathol. 2001, 159:1129-1135.
96. Kim H.C., Roh S.A., Ga I.H., et al. CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J. Gastroenterol. Hepatol. 2005, 20:1920-1926.
97. Kim Y.H., Kakar S., Cun L., et al. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int. J. Cancer 2008, 123:2587-2593.
98. Tanaka N., Huttenhower C., Nosho K., et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am. J. Pathol. 2010, 177:2731-2740.
99. van Vlodrop I.J., Niessen H.E., Derks S., et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!. Clin. Cancer Res. 2011, 17:4225-4231.
100. Grady W.M. CIMP and colon cancer gets more complicated. Gut 2007, 56:1498-1500.
101. Ogino S., Chan A.T., Fuchs C.S., et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2010, 60:397-411.
102. Hughes L.A., Simons C.C., van den Brandt P.A., et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One 2011, 6:e18571.
103. Slattery M.L., Curtin K., Sweeney C., et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int. J. Cancer 2007, 120:656-663.
104. Slattery M.L., Wolff R.K., Herrick J.S., et al. Alcohol consumption and rectal tumor mutations and epigenetic changes. Dis. Colon Rectum 2010, 53:1182-1189.
105. Hughes L.A., van den Brandt P.A., de Bruine A.P., et al. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One 2009, 4:e7951.
106. de Vogel S., Wouters K.A., Gottschalk R.W., et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3086-3096.
107. Van Guelpen B., Dahlin A.M., Hultdin J., et al. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control 2011, 21:557-566.
108. Kawakami K., Ruszkiewicz A., Bennett G., et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br. J. Cancer 2006, 94:593-598.
109. Wallace K., Grau M.V., Levine A.J. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev. Res. 2010, 3:1552-1564.
110. Paun B.C., Kukuruga D., Jin Z. Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer 2010, 116:4495-4501.